StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences R&D by cost type

R&D by cost type — Personnel, infrastructure and other support costs ($M) ($M)

QuarterlyAnnual

Gilead Sciences R&D by cost type: $1,146M in Q2 2026, up 34.0% from a year earlier. That is the highest of the 25 quarters on record here.

Latest, Q2 2026
1,146
Period ended Jun 30, 2026
Change on a year earlier
+34.0%
855 in Q2 2025
History
25 quarters
Since Q1 2020
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“|| Personnel, infrastructure and other support costs | $ | 1,146 | $ | 855 | 34 | % | $ | 2,007 | $ | 1,709 | 17 | %”

Source: Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K MD&A Research and Development Expenses.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedR&D by cost type — Personnel, infrastructure and other support costs ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,146+34.0%Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q1 2026Mar 31, 2026861+0.8%Form 10-Q (gild-20260331.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025911-4.5%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
Q3 2025Sep 30, 2025807-0.1%Form 10-Q (gild-20250930.htm, filed 2025-11-07) ↗
Q2 2025Jun 30, 2025855+3.0%Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q1 2025Mar 31, 2025854-11.3%Form 10-Q (gild-20260331.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 2024954+15.9%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
Q3 2024Sep 30, 2024808+4.1%Form 10-Q (gild-20250930.htm, filed 2025-11-07) ↗
Q2 2024Jun 30, 2024830+5.3%Form 10-Q (gild-20250630.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 2024963+17.9%Form 10-Q (gild-20250331.htm, filed 2025-05-07) ↗
Q4 2023Dec 31, 2023823+2.0%Form 10-K (gild-20241231.htm, filed 2025-02-28) ↗
Q3 2023Sep 30, 2023776+12.8%Form 10-Q (gild-20240930.htm, filed 2024-11-12) ↗
Q2 2023Jun 30, 2023788+24.3%Form 10-Q (gild-20240630.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 2023817+19.8%Form 10-Q (gild-20240331.htm, filed 2024-05-08) ↗
Q4 2022Dec 31, 2022807–Form 10-K (gild-20231231.htm, filed 2024-02-23) ↗
Q3 2022Sep 30, 2022688+29.1%Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences R&D by cost type ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd-personnel-infra

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.